title: Can patients maintain their use of everolimus until lung transplantation?
authors.affiliation: 1 Pulmonary Division, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, SP, Brazil 2 Thoracic Surgery Division, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: André Nathan
authors.initials: AN
authors.lastname: Costa
authors.forename: Bruno Guedes
authors.initials: BG
authors.lastname: Baldi
authors.forename: Ricardo Henrique
authors.initials: RH
authors.lastname: de Oliveira Braga Teixeira
authors.forename: Marcos Naoyuki
authors.initials: MN
authors.lastname: Samano
authors.forename: Carlos Roberto Ribeiro
authors.initials: CR
authors.lastname: de Carvalho
mesh_terms: D000328:Adult; D065095:Calcineurin Inhibitors / Q000009:adverse effects; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016040:Lung Transplantation / Q000009:adverse effects; D008297:Male; D012086:Reoperation; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus